ES2549690B1 - Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz - Google Patents

Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz Download PDF

Info

Publication number
ES2549690B1
ES2549690B1 ES201300887A ES201300887A ES2549690B1 ES 2549690 B1 ES2549690 B1 ES 2549690B1 ES 201300887 A ES201300887 A ES 201300887A ES 201300887 A ES201300887 A ES 201300887A ES 2549690 B1 ES2549690 B1 ES 2549690B1
Authority
ES
Spain
Prior art keywords
high specificity
modified antibodies
multipurpose
highly safe
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201300887A
Other languages
English (en)
Other versions
ES2549690A2 (es
ES2549690B8 (es
ES2549690R1 (es
Inventor
Juan LÓPEZ DE SILANES PÉREZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INOSAN BIOPHARMA S A
Inosan Biopharma Sa
Original Assignee
INOSAN BIOPHARMA S A
Inosan Biopharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INOSAN BIOPHARMA S A, Inosan Biopharma Sa filed Critical INOSAN BIOPHARMA S A
Publication of ES2549690A2 publication Critical patent/ES2549690A2/es
Publication of ES2549690R1 publication Critical patent/ES2549690R1/es
Publication of ES2549690B1 publication Critical patent/ES2549690B1/es
Application granted granted Critical
Publication of ES2549690B8 publication Critical patent/ES2549690B8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz.#La invención se relaciona con la producción y desarrollo de una formulación inyectable liofilizada de anticuerpos modificados o variantes de ellos, altamente específicos neutralizantes de mezclas heterólogas de proteínas, péptidos y otros componentes orgánicos e inorgánicos que tienen diferentes actividades específicas y pueden incluir pero no se limitan a venenos de animales ponzoñosos. Por conveniencia haremos referencia a venenos, pero se incluyen todo tipo de venenos de animales terrestres y marinos. También está dirigida al método de producción que incluye la hiperinmunización de mamíferos para la producción de anticuerpos altamente específicos, el proceso de modificación (fragmentación) y purificación, y finalmente la formulación inyectable liofilizada, que le confiere propiedades de alta pureza y alta especificidad.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
    imagen2
ES201300887A 2012-10-18 2013-09-27 Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz Active ES2549690B8 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX/A/2012/012132 2012-10-18
MX2012012132A MX367136B (es) 2012-10-18 2012-10-18 Proceso para purificar fragmentos de anticuerpos polivalentes derivados de plasma hiperinmune.

Publications (4)

Publication Number Publication Date
ES2549690A2 ES2549690A2 (es) 2015-10-30
ES2549690R1 ES2549690R1 (es) 2016-01-11
ES2549690B1 true ES2549690B1 (es) 2016-09-21
ES2549690B8 ES2549690B8 (es) 2018-06-21

Family

ID=50097480

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201300887A Active ES2549690B8 (es) 2012-10-18 2013-09-27 Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz

Country Status (4)

Country Link
US (2) US10538577B2 (es)
ES (1) ES2549690B8 (es)
FR (1) FR2997084A1 (es)
MX (1) MX367136B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3680252A4 (en) 2017-10-02 2021-04-28 Laboratorios Silanes, S.A. de C.V. HIGH PERFORMANCE PROCESS FOR PREPARATION OF POISON ANTIDOTS WITH F (AB ') - 2 ANTIBODY FRAGMENTS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2065196A (en) 1934-10-09 1936-12-22 Parfentjev Ivan Alexandrovich Method for purification of antitoxins and the like
US2123198A (en) 1936-10-23 1938-07-12 Lederle Lab Inc Treatment of antitoxins and the like
US2175090A (en) 1938-06-22 1939-10-03 Lederie Lab Inc Purification of antibody compositions
US4849352A (en) 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
IN188098B (es) 2000-03-09 2002-08-17 Serum Inst India Ltd
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
WO2004007695A2 (en) 2002-03-08 2004-01-22 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof
EP1651266B1 (en) 2003-07-25 2010-03-03 Laboratorios Silanes, S.A. de C.V. Administration of anti-tnf-alpha f(ab')2 antibody fragments
MXPA04008435A (es) 2004-08-31 2006-03-02 Univ Mexico Nacional Autonoma Inmunogeno y anti-veneno contra el veneno de la arana violinista.
MXPA06003717A (es) 2006-04-03 2006-09-29 Silanes Sa De Cv Lab Composiciones oftalmicas de proteinas inhibidoras de citocinas implicadas en procesos inflamatorios o inmunologicos.
CN101816789B (zh) 2010-04-08 2012-09-05 成都军区疾病预防控制中心军事医学研究所 抗蝰蛇蛇毒冻干血清及制备方法

Also Published As

Publication number Publication date
ES2549690A2 (es) 2015-10-30
US20160368969A1 (en) 2016-12-22
ES2549690B8 (es) 2018-06-21
US20200190166A1 (en) 2020-06-18
MX367136B (es) 2019-08-06
US10538577B2 (en) 2020-01-21
FR2997084A1 (fr) 2014-04-25
MX2012012132A (es) 2013-12-08
ES2549690R1 (es) 2016-01-11

Similar Documents

Publication Publication Date Title
PH12017501287A1 (en) A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
NZ735019A (en) Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
CL2015000420A1 (es) Anticuerpo de unión a gfr alfa 3 (gfra3); ácido nucleico que lo codifica; vector; método para producirlo; composición farmacéutica que lo comprende; y uso para tratar una afección o enfermedad relacionada con gfra3.
AR107290A1 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
BR112013005136A2 (pt) composições e métodos para controlar pragas de nematodeo
UY36157A (es) Composiciones pesticidas y procedimientos relacionados con las mismas
NZ731103A (en) Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
WO2014020129A3 (en) Allatostatin-b peptides for inducing the settlement of lophotrochozoan marine larvae
CL2012002438A1 (es) Anticuerpo aislado que se une a peptido ciclico derivado de peptido betaamiloide (ab); inmunoconjugado que comprende dicho anticuerpo; metodo para tratar o prevenir enfermedad de alzheimer que comprende el anticuerpo antes mencionado; kit que comprende el anticuerpo.
NZ728484A (en) Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto
NZ726907A (en) Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto
WO2013001285A3 (en) Fmdv vp1 peptides
UA120999C2 (uk) Естери оксаборолу та їх використання
DOP2012000232A (es) Proteínas de unión a antigeno especificas para el componente amiloide serico p
BR112019000946A2 (pt) compostos para imagiologia dos agregados da proteína tau
BR112015008972A2 (pt) vacina para prevenir doença de edema em suínos
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
WO2014153168A3 (en) Porcine astrovirus sequences and uses thereof
ES2549690B1 (es) Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz
PH12015502072B1 (en) Nutritional compositions containing a peptide component and uses thereof
MX2016009747A (es) Vacunas contra el reovirus aviar.
WO2014111840A3 (en) Peptide
AR092102A1 (es) Hidrolizado de proteinas
ES2441880B1 (es) Composición basada en polipéptidos para el tratamiento de miasis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2549690

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20160921